Astec Lifesciences is currently trading at Rs 18.25, up by 0.70 points or 3.99% from its previous closing of Rs 17.55 on the BSE.
The scrip opened at Rs 18.00 and has touched a high and low of Rs 18.30 and Rs 17.85 respectively. So far 2898 shares were traded on the counter.
The BSE group 'B' stock of face value Rs 10 has touched a 52 week high of Rs 37.20 on 02-Nov-2012 and a 52 week low of Rs 14.45 on 30-Apr-2013.
Last one week high and low of the scrip stood at Rs 19.80 and Rs 14.45 respectively. The current market cap of the company is Rs 33.02 crore.
The promoters holding in the company stood at 56.93% while Non-Institutions held 43.07% respectively.
Credit rating agency, ICRA has reaffirmed the ‘BBB-’ rating assigned to Rs 16 crore, long-term loans, $3.91 million ECB loan and the Rs 34.0 crore long-term, fund-based bank facilities of Astec Lifesciences. The outlook on the long-term rating is stable. The rating agency has also reaffirmed the A3 rating assigned to the Rs 20.0 crore, short term, non-fund based bank facilities of Astec.
The reaffirmation of the ratings favourably factor in the expertise of the promoters with over three decades of experience in the agrochemicals industry and the company’s established market position in the manufacture and sale of triazole fungicides.
Astec LifeSciences is a producer of agrochemicals and pharmaceutical intermediates. The company manufactures a wide range of Agrochemical active ingredients and pharmaceutical intermediates.
| Company Name | CMP |
|---|---|
| UPL | 665.00 |
| PI Industries | 3144.45 |
| Bayer CropScience | 4900.45 |
| Sharda Cropchem | 1109.70 |
| Sumitomo Chemical | 441.95 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: